Tissue-engineered constructs (TECs) seeded with mesenchymal stem cells (MSCs) represent a therapy for large bone defects. However, massive cell death in TECs in the early postimplantation period prompted us to investigate the osteoinductive mechanism of TECs. Previous studies demonstrated that stem cell extracts retained equivalent levels of bioactive proteins and exhibited an osteoinductive nature similar to that of intact cells. These data led us to hypothesize that despite the massive cell death in TECs, devitalized MSC-derived proteins remain on the scaffolds and are released to improve cell function. Here, TECs were prepared using demineralized bone matrix seeded with human umbilical cord Wharton's jelly-derived MSCs (hWJMSCs), and the cells seeded in TECs were devitalized by lyophilizing the TECs. Scanning electron microscopy, BCA protein assays, quantitative cytokine array analysis and immunofluorescent staining indicated that approximately 3 mg/cm 3 of total protein and 49 types of cytokines derived from hWJMSCs were preserved in the lyophilized TECs (LTECs). The sustainable release of total protein and cytokines from LTECs lasted for more than 2 weeks. The released protein improved the osteogenic behavior of and gene expression in MSCs. Furthermore, the lyophilized hWJMSC-derived proteins had immunoregulatory properties similar to those of live MSCs in mixed lymphocyte reactions. Collectively, we present a novel perspective on the osteoinductive mechanism of TECs and introduce LTECs as new systems for delivering multiple cytokines to enhance MSC behavior. Keywords: lyophilized tissue-engineered construct; bioactive protein; sustained release; osteogenesis Large bone defects caused by traumatic bone injury, tumor resection, and osteitis are a challenge confronted in orthopedic surgery. Tissue-engineered constructs (TECs) seeded with mesenchymal stem cells (MSCs) could promote osteogenesis in vivo, and these TECs are a promising therapy for large bone defects. 1 However, several obstacles still impede the widespread clinical application of TECs, including the fact that the osteoinductive mechanism is unclear. It is possible that the osteoinductive mechanism involves the differentiation of MSCs followed by the synthesis and deposition of bone matrix on the scaffold substrate. 2 Alternatively, MSCs may recruit endogenous cells to produce bone matrix by secreting cytokines. 3 However, most studies showed that massive MSC death (from 70% to 100%) in TECs occurred in the first week of the postimplantation period because of local tissue ischemia. 4,5 This observation is inconsistent with the aforementioned mechanisms. Moreover, recent studies showed that stem cell-derived extracts contained a large amount of protein and retained some properties similar to those of intact cells, such as immunoregulatory activity and osteoinductive capacity, among other characteristics. 6,7 It is logical to assume that proteins derived from the devitalized MSCs in TECs should possess these modulatory properties. Therefo...